Szturz P - Search Results

1

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

Evrard D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, Abitbol C, Paradis V, Raymond E, Albert S, Barry B, Faivre S. Evrard D, et al. Among authors: szturz p. Oral Oncol. 2019 Jan;88:29-38. doi: 10.1016/j.oraloncology.2018.10.040. Epub 2018 Nov 20. Oral Oncol. 2019. PMID: 30616794 Review.

2

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.

Szturz P, Raymond E, Faivre S. Szturz P, et al. Oral Oncol. 2016 Aug;59:e12-e14. doi: 10.1016/j.oraloncology.2016.05.017. Epub 2016 Jun 11. Oral Oncol. 2016. PMID: 27302885 No abstract available.

3

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

Szturz P, Faivre S. Szturz P, et al. Oral Oncol. 2016 Nov;62:e3-e4. doi: 10.1016/j.oraloncology.2016.08.007. Epub 2016 Aug 28. Oral Oncol. 2016. PMID: 27578499 No abstract available.

4

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S. Szturz P, et al. Crit Rev Oncol Hematol. 2017 Mar;111:39-51. doi: 10.1016/j.critrevonc.2017.01.004. Epub 2017 Jan 12. Crit Rev Oncol Hematol. 2017. PMID: 28259294 Review.

5

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

Szturz P, Budíková M, Vermorken JB, Horová I, Gál B, Raymond E, de Gramont A, Faivre S. Szturz P, et al. Oral Oncol. 2017 Nov;74:68-76. doi: 10.1016/j.oraloncology.2017.09.009. Epub 2017 Sep 27. Oral Oncol. 2017. PMID: 29103754 Review.

6

Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.

Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, Adelstein D, Vermorken JB. Szturz P, et al. Oral Oncol. 2018 Jan;76:52-60. doi: 10.1016/j.oraloncology.2017.11.025. Epub 2017 Dec 8. Oral Oncol. 2018. PMID: 29290286

7

Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice.

Szturz P, Cristina V, Herrera Gómez RG, Bourhis J, Simon C, Vermorken JB. Szturz P, et al. Front Oncol. 2019 Jun 11;9:464. doi: 10.3389/fonc.2019.00464. eCollection 2019. Front Oncol. 2019. PMID: 31245288 Free PMC article. Review.

8

Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.

Szturz P, Vermorken JB. Szturz P, et al. Oral Oncol. 2020 Feb;101:104492. doi: 10.1016/j.oraloncology.2019.104492. Epub 2019 Dec 11. Oral Oncol. 2020. PMID: 31837576 Review.

9

Overcoming frailty in recurrent and metastatic head and neck cancer.

Szturz P, Vermorken JB. Szturz P, et al. Oral Oncol. 2020 Oct;109:104636. doi: 10.1016/j.oraloncology.2020.104636. Epub 2020 Mar 12. Oral Oncol. 2020. PMID: 32171664 No abstract available.

10

Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity.

Szturz P, Van Laer C, Simon C, Van Gestel D, Bourhis J, Vermorken JB. Szturz P, et al. Front Oncol. 2020 May 6;10:688. doi: 10.3389/fonc.2020.00688. eCollection 2020. Front Oncol. 2020. PMID: 32435619 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters